Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Immunol
Hlavní autoři: Lancman, Guido, Arinsburg, Suzanne, Jhang, Jeffrey, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richter, Joshua, Chari, Ajai
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Immunology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249335/
https://ncbi.nlm.nih.gov/pubmed/30498492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02616
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky